Control of new synthetic drugs, designer drugs

This document consists of the reports from the Commission to the Council called for by the Joint Action on New Synthetic Drugs (97/396/JAI) concerning : - TMA-2 (2,4,5-trimethoxyamphetamine); - 2C-I (2,5-dimethoxy-4-iodophenethylamine); - 2C-T-2 (2,5-dimethoxy-4-ethylthiophenethylamine); - 2C-T-7 (2,5-dimethoxy-4-propylthiophenethylamine). On the 8th of April 2003, the European Commission received from the EMCDDA the report on the risk assessment of these 4 substances. At present there are a few animal and no human data concerning general toxicity, reproductive toxicity, neurotoxicity or the mutagenicity and carcinogenic potential of these 4 substances. There is currently no evidence of negative social consequences nor is there specific evidence on the consequences of the use of these substances that could be linked to disorderly conduct, acquisitive crime or violence. Basing itself solely on the risk assessment report on TMA-2, 2C-I, 2C-T-2 and 2C-T-7 and the principle of proportionality, the Commission concludes that it is not appropriate to present an initiative to the Council to propose that these substances be submitted to control measures at the EU level, as provided for by Article 5(1) of the Joint Action on New Synthetic Drugs. But the Commission will encourage the EMCDDA and Europol to continue monitoring trends in recreational use of these substances as part of the early warning system provided for in the Joint Action, and to inform the Horizontal Drugs Group should they find new elements, particularly evidence of a threat to public health or a social risk.�